Malignant Peripheral Nerve Sheath Tumor (MPNST)
A malignant peripheral nerve sheath tumor (MPNST) is a rare, aggressive soft tissue sarcoma arising from the cells of the peripheral nerve sheath, often linked to Neurofibromatosis Type 1.
Wissenswertes über "Malignant Peripheral Nerve Sheath Tumor"
A malignant peripheral nerve sheath tumor (MPNST) is a rare, aggressive soft tissue sarcoma arising from the cells of the peripheral nerve sheath, often linked to Neurofibromatosis Type 1.
Definition
A malignant peripheral nerve sheath tumor (abbreviated MPNST) is a rare and highly aggressive form of soft tissue sarcoma that originates from Schwann cells or other elements of the peripheral nerve sheath. MPNSTs account for approximately 5–10% of all soft tissue sarcomas. While they can arise sporadically, roughly 50% of cases are associated with the hereditary condition Neurofibromatosis Type 1 (NF1).
Causes and Risk Factors
The development of an MPNST is multifactorial. Key risk factors include:
- Neurofibromatosis Type 1 (NF1): Individuals with this inherited condition carry a lifetime risk of 8–13% for developing an MPNST, due to loss-of-function mutations in the NF1 tumor suppressor gene encoding the protein neurofibromin.
- Prior radiation therapy: Previous exposure to ionizing radiation in a given body region significantly increases the risk of radiation-induced MPNST.
- Sporadic occurrence: Approximately 40–50% of MPNSTs arise spontaneously without an identifiable underlying condition.
- Malignant transformation: In rare instances, a pre-existing benign plexiform neurofibroma can undergo malignant transformation into an MPNST.
Symptoms
Clinical signs of an MPNST are often nonspecific and vary depending on the size, location, and growth rate of the tumor. Common symptoms include:
- A painless or painful palpable mass in the trunk, extremities, or head and neck region
- Neurological deficits such as numbness, tingling, or weakness due to nerve compression
- Rapid enlargement of a previously known lesion
- General symptoms such as unintentional weight loss, fatigue, or night sweats in advanced disease
Diagnosis
Diagnosing an MPNST requires a combination of clinical evaluation, imaging, and histopathological confirmation:
Imaging
- MRI (Magnetic Resonance Imaging): The preferred modality for assessing tumor extent, location, and relationship to surrounding structures.
- PET-CT (Positron Emission Tomography with CT): Used to evaluate metabolic activity and detect distant metastases.
- CT of the chest and abdomen: Performed for staging and to identify metastases, particularly in the lungs and liver.
Biopsy and Pathology
- Biopsy: Essential for histological confirmation. MPNSTs typically show spindle-shaped cells with a high mitotic rate under microscopy.
- Immunohistochemistry and molecular pathology: Used to differentiate MPNSTs from other soft tissue sarcomas; loss of H3K27me3 expression serves as a key diagnostic marker.
Treatment
Treatment of MPNST depends on the stage, location, and overall health of the patient. A multimodal approach is usually required:
Surgery
Complete surgical resection with clear margins (R0 resection) is the primary potentially curative treatment. Incomplete resection is associated with a significantly higher risk of local recurrence.
Radiation Therapy
Adjuvant radiation therapy is commonly used following surgery to reduce the risk of local relapse, especially when surgical margins are close or unclear.
Chemotherapy
For metastatic or inoperable MPNSTs, systemic chemotherapy may be employed. Commonly used agents include doxorubicin and ifosfamide, though overall response rates remain limited.
Targeted Therapies and Clinical Trials
Given the poor prognosis in advanced disease, various targeted and immunotherapeutic approaches are being investigated in clinical trials. MEK inhibitors such as selumetinib, already approved for NF1-associated plexiform neurofibromas, are among the most promising candidates.
Prognosis
The overall prognosis for MPNST is unfavorable. Five-year survival rates range from approximately 20% to 50%, depending on stage and resectability. NF1-associated MPNSTs tend to carry a worse prognosis than sporadic cases. Key prognostic factors include the completeness of surgical resection, tumor size, and the presence of distant metastases.
References
- Widemann BC, Italiano A. Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. Journal of Clinical Oncology, 2018.
- Evans DG et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. Journal of Medical Genetics, 2002.
- WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. WHO Classification of Tumours, 5th Edition. IARC Press, Lyon, 2020.
Best-selling products
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, probiotic lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryPancreatic Hormone Replacement
Cell Membrane Protective Protein
Gut Microbiome Optimization
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Cologne list
Calorie content
Related search terms: Malignant Peripheral Nerve Sheath Tumor + Malignant Peripheral Nerve Sheath Tumour + MPNST